In addition, the TGF-β inhibitor SB431542 and CASC2c could repress ERK signaling and inhibit cell proliferation in HCC, which provide a novel therapeutic target for HCC [65, 112]. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.